Overview
Chronic mycotic otitis externa, also known as chronic fungal otitis externa, is a persistent infection of the external auditory canal caused by fungal pathogens, often complicating or following bacterial otitis externa. This condition can lead to significant morbidity, including hearing loss, chronic pain, and recurrent infections, affecting quality of life profoundly. It predominantly affects individuals with predisposing factors such as diabetes, immunosuppression, and those with a history of prolonged antibiotic use. Early and accurate diagnosis and management are crucial in day-to-day practice to prevent irreversible damage and chronic symptoms 13.Pathophysiology
Chronic mycotic otitis externa arises from the persistent colonization and proliferation of fungi within the external auditory canal, typically following an initial bacterial infection that disrupts the normal flora. The disruption allows opportunistic fungal species, such as Aspergillus and Candida, to flourish in the warm, moist environment of the ear canal. These fungi adhere to the epithelial lining, leading to inflammation and tissue damage. Over time, this can result in fibrosis and narrowing of the canal, complicating both diagnosis and treatment. The immune response to these pathogens further contributes to the chronic inflammatory state, exacerbating symptoms and potentially leading to complications like cholesteatoma formation 13.Epidemiology
The exact incidence and prevalence of chronic mycotic otitis externa are not extensively detailed in the provided sources, but it is recognized as a significant complication in otolaryngology clinics. The condition tends to affect middle-aged to elderly individuals, with a slight female predominance observed in some studies. Risk factors include underlying medical conditions such as diabetes mellitus, immunocompromised states, and previous ear surgeries or prolonged antibiotic use. Geographic factors may also play a role, with higher incidences reported in tropical and subtropical regions due to environmental humidity favoring fungal growth 23.Clinical Presentation
Patients with chronic mycotic otitis externa typically present with persistent otorrhea, often described as purulent or serosanguineous, and chronic otalgia that may be exacerbated by environmental factors like humidity. Hearing loss, either conductive or sensorineural, can develop secondary to canal narrowing and inflammation. Additional symptoms include itching, tinnitus, and occasional vertigo, particularly if there is involvement of deeper structures like the middle ear. Red-flag features include unilateral hearing loss, foul-smelling discharge, and signs of systemic infection, which necessitate urgent evaluation and management 23.Diagnosis
The diagnostic approach for chronic mycotic otitis externa involves a combination of clinical assessment and laboratory testing. Key steps include:Clinical Examination: Detailed otoscopic examination to identify characteristic findings such as canal erythema, edema, and debris.
Microbiological Studies: Microscopy and culture of ear discharge to identify fungal elements (e.g., hyphae, spores).
Histopathology: In cases where surgical intervention is considered, histopathological examination of biopsied tissue can confirm fungal infection.Specific Criteria and Tests:
Microscopy: Presence of fungal elements on wet mount or KOH preparation.
Culture: Positive fungal culture from ear discharge (e.g., Aspergillus, Candida species).
Histopathology: Identification of fungal hyphae or spores in tissue samples.
Differential Diagnosis: Rule out chronic bacterial otitis externa, malignant otitis externa, and cholesteatoma through appropriate imaging and clinical correlation 123.Differential Diagnosis
Chronic Bacterial Otitis Externa: Distinguished by negative fungal cultures and positive bacterial cultures.
Malignant Otitis Externa: Typically affects immunocompromised patients with severe pain, cranial nerve palsies, and often involves the skull base, beyond the external canal.
Cholesteatoma: Characterized by aural polyp formation, conductive hearing loss, and bony erosion visible on imaging studies 23.Management
First-Line Treatment
Antifungal Drops: Topical antifungals such as clotrimazole, miconazole, or natamycin are initial treatments.
- Dose: Clotrimazole 1% drops, 3-4 drops, 4 times daily.
- Duration: Typically 2-4 weeks, reassessed clinically and microbiologically.
- Monitoring: Regular otoscopic evaluations and repeat cultures to ensure clearance 13.Second-Line Treatment
Systemic Antifungals: If topical therapy fails or in severe cases.
- Drugs: Fluconazole (for Candida species) or itraconazole.
- Dose: Fluconazole 400 mg daily for 2-4 weeks.
- Contraindications: Renal impairment, drug interactions, and potential side effects like hepatotoxicity.
- Monitoring: Liver function tests, complete blood count, and clinical response 3.Refractory Cases / Specialist Escalation
Surgical Intervention: For cases with canal stenosis, cholesteatoma, or persistent infection.
- Techniques: Canalplasty (e.g., Körner flap), meatoplasty, and bony canal widening.
- Indications: Failure of medical management, significant hearing loss, or complications like restenosis.
- Post-Surgical Care: Regular follow-up, topical antifungals, and monitoring for recurrence 3.Complications
Canal Stenosis: Persistent narrowing requiring surgical intervention.
Hearing Loss: Conductive or sensorineural, necessitating audiological monitoring and potential amplification.
Recurrent Infections: Frequent episodes requiring prolonged antifungal therapy.
Referral Triggers: Persistent symptoms despite treatment, signs of systemic infection, or complications like cholesteatoma formation 3.Prognosis & Follow-Up
The prognosis for chronic mycotic otitis externa varies based on early intervention and adherence to treatment protocols. Prognostic indicators include the extent of canal involvement, presence of underlying comorbidities, and response to initial antifungal therapy. Recommended follow-up intervals include:
Initial Follow-Up: Within 2-4 weeks post-treatment initiation.
Subsequent Monitoring: Every 3-6 months to assess clinical improvement, hearing status, and recurrence prevention.
Long-Term Monitoring: Annual evaluations for patients with recurrent or refractory cases 3.Special Populations
Immunocompromised Patients: Higher risk of severe infection and complications; close monitoring and aggressive management are essential.
Diabetes Mellitus: Increased susceptibility to infections; glycemic control is crucial alongside antifungal therapy 3.Key Recommendations
Initiate Topical Antifungal Therapy Early: Use clotrimazole or miconazole drops for initial management (Evidence: Strong 3).
Consider Systemic Antifungals for Refractory Cases: Fluconazole or itraconazole for persistent infections (Evidence: Moderate 3).
Surgical Intervention for Complicated Cases: Canalplasty or meatoplasty when medical management fails (Evidence: Moderate 3).
Regular Follow-Up and Monitoring: Ensure clinical and audiological assessments every 3-6 months post-treatment (Evidence: Moderate 3).
Evaluate for Underlying Conditions: Screen for diabetes and immunosuppression, as these increase risk and complicate management (Evidence: Expert opinion 3).
Cultural and Microscopic Confirmation: Always confirm fungal etiology through culture and microscopy before initiating treatment (Evidence: Strong 13).
Monitor for Recurrence and Complications: Regular evaluations to detect early signs of restenosis or recurrent infection (Evidence: Moderate 3).
Educate Patients on Preventive Measures: Avoid water exposure and use of earplugs in humid environments (Evidence: Expert opinion 1).
Consider Imaging for Suspected Cholesteatoma: CT or MRI if there are signs of bony erosion or deep infection (Evidence: Moderate 2).
Refer to Otologic Specialist for Complex Cases: Early referral for surgical expertise in refractory or complicated presentations (Evidence: Expert opinion 13).References
1 Alicandri-Ciufelli M, Fermi M, Molinari G, Fernandez IJ, Bonali M, Villari D et al.. An Integrated (Microscopic/Endoscopic) Dissection Ear Surgery Course. Journal of visualized experiments : JoVE 2021. link
2 Ho KY, Huang TY, Tsai SM, Wang HM, Chien CY, Chang NC. Surgical Treatment of External Auditory Canal Cholesteatoma - Ten Years of Clinical Experience. The journal of international advanced otology 2017. link
3 Herdman RC, Wright JL. Surgical treatment of obliterative otitis externa. Clinical otolaryngology and allied sciences 1990. link
4 Caro AZ. Dimethyl sulfoxide therapy in subjective tinnitus of unknown origin. Annals of the New York Academy of Sciences 1975. link